Tyra Biosciences
TYRA
121 hedge funds and large institutions have $542M invested in Tyra Biosciences in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 62 increasing their positions, 20 reducing their positions, and 14 closing their positions.
210% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 20
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
8% more capital invested
Capital invested by funds: $500M → $542M (+$42M)
5.68% more ownership
Funds ownership: 100.91% → 106.59% (+5.7%)
3% more funds holding
Funds holding: 117 → 121 (+4)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$20.4M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$14.8M |
| 3 |
SCM
Sio Capital Management
New York
|
+$3.74M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.23M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$2.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.1M |
| 2 |
O
OrbiMed
New York
|
-$9.01M |
| 3 |
CPX
Canaan Partners XI
Menlo Park,
California
|
-$5.1M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$4.27M |
| 5 |
VPC
Vestal Point Capital
New York
|
-$2.14M |
TYRA Hedge Fund Activity: Q2 2025 in Review
121 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q2 2025, worth a combined $542M — up 8.4% from $500M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TYRA positions and 14 closed out — a net gain of 4 holders — while 62 added to existing stakes and 20 trimmed.
The largest buyer was Commodore Capital, adding an estimated $20.4M. The largest seller was Fidelity Investments, cutting an estimated $16.1M.
- 121 institutional investors held Tyra Biosciences (TYRA) as of Q2 2025, up from 117 in Q1 2025.
- Funds reported $542M of Tyra Biosciences stock for Q2 2025, up 8.4% quarter-over-quarter.
- 18 funds opened new Tyra Biosciences positions in Q2 2025 and 14 closed out, a net change of +4 holders.
- The largest Tyra Biosciences buyer in Q2 2025 was Commodore Capital, an estimated $20.4M added.
- The largest Tyra Biosciences seller in Q2 2025 was Fidelity Investments, an estimated $16.1M sold.
Based on aggregated 13F filings for Q2 2025.